Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyCellularComponentaxon

FKBP15 HDAC5 MAP1A PCLO ROR1 N4BP3 MAP3K12 KLHL20 PPP1R2 PPP1R2B SCN5A DOCK7 PRKCZ DMD

6.14e-058919714GO:0030424
GeneOntologyCellularComponentgrowth cone

FKBP15 HDAC5 PCLO MAP3K12 PPP1R2 PPP1R2B DOCK7

1.46e-04245977GO:0030426
GeneOntologyCellularComponentsite of polarized growth

FKBP15 HDAC5 PCLO MAP3K12 PPP1R2 PPP1R2B DOCK7

1.78e-04253977GO:0030427
GeneOntologyCellularComponentdistal axon

FKBP15 HDAC5 MAP1A PCLO ROR1 MAP3K12 PPP1R2 PPP1R2B DOCK7

1.91e-04435979GO:0150034
GeneOntologyCellularComponentmatrix side of mitochondrial inner membrane

AMBP DMD

5.86e-048972GO:0099617
DomainZfx_Zfy_act

ZFX ZNF711

7.82e-053962PF04704
DomainTranscrp_activ_Zfx/Zfy-dom

ZFX ZNF711

7.82e-053962IPR006794
DomainPkinase_Tyr

FLT4 ROR1 MAP3K12 KDR MAP3K21

5.38e-04129965PF07714
DomainTyr_kinase_rcpt_3_CS

FLT4 KDR

7.17e-048962IPR001824
DomainRECEPTOR_TYR_KIN_III

FLT4 KDR

7.17e-048962PS00240
DomainSer-Thr/Tyr_kinase_cat_dom

FLT4 ROR1 MAP3K12 KDR MAP3K21

7.30e-04138965IPR001245
DomainTyrKc

FLT4 ROR1 KDR MAP3K21

1.10e-0388964SM00219
DomainTyr_kinase_cat_dom

FLT4 ROR1 KDR MAP3K21

1.10e-0388964IPR020635
Domain-

DCAF8 GRWD1 WDR7 WDR55 TEP1 DCAF5 SEMA5B

1.65e-033339672.130.10.10
DomainWD40/YVTN_repeat-like_dom

DCAF8 GRWD1 WDR7 WDR55 TEP1 DCAF5 SEMA5B

1.71e-03335967IPR015943
DomainWD40

DCAF8 GRWD1 WDR7 WDR55 TEP1 DCAF5

2.20e-03259966PF00400
DomainWD40

DCAF8 GRWD1 WDR7 WDR55 TEP1 DCAF5

2.60e-03268966SM00320
DomainWD40_repeat

DCAF8 GRWD1 WDR7 WDR55 TEP1 DCAF5

2.80e-03272966IPR001680
Domainig

FLT4 CD22 CD33 NECTIN4 KDR

2.99e-03190965PF00047
DomainImmunoglobulin

FLT4 CD22 CD33 NECTIN4 KDR

2.99e-03190965IPR013151
DomainWD_REPEATS_1

DCAF8 GRWD1 WDR7 WDR55 TEP1 DCAF5

3.12e-03278966PS00678
DomainChannel_four-helix_dom

CACNA1E KCNG4 SCN5A

3.15e-0357963IPR027359
Domain-

CACNA1E KCNG4 SCN5A

3.15e-03579631.20.120.350
DomainWD_REPEATS_2

DCAF8 GRWD1 WDR7 WDR55 TEP1 DCAF5

3.18e-03279966PS50082
DomainWD_REPEATS_REGION

DCAF8 GRWD1 WDR7 WDR55 TEP1 DCAF5

3.18e-03279966PS50294
DomainTSP_1

ADGRB2 SEMA5B ADAMTS20

4.18e-0363963PF00090
DomainWD40_repeat_dom

DCAF8 GRWD1 WDR7 WDR55 TEP1 DCAF5

4.31e-03297966IPR017986
DomainTSP1

ADGRB2 SEMA5B ADAMTS20

4.57e-0365963SM00209
DomainTSP1_rpt

ADGRB2 SEMA5B ADAMTS20

4.57e-0365963IPR000884
DomainTSP1

ADGRB2 SEMA5B ADAMTS20

4.57e-0365963PS50092
DomainF-box

FBXO40 FBXO38 FBH1

4.97e-0367963PF00646
Pubmed

Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.

FKBP15 INTU ZNF536 ANKFY1 HDAC5 WDR7 SEPTIN9 DCAF5 TENM4 DOCK7 BOD1L1 PCNT

1.63e-09407971212693553
Pubmed

Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.

BDP1 CABLES2 INTU HIVEP2 DCAF8 CACNA2D2 SEPTIN9 LAMA3 TEP1 ATP10A MAP3K12 PLEKHM1 FAF1 BOD1L1 PRKCZ PCNT

3.53e-061489971628611215
Pubmed

BOD1L mediates chromatin binding and non-canonical function of H3K4 methyltransferase SETD1A.

SETD1A BOD1L1

7.70e-06297238989615
Pubmed

Identification and characterization of two distinct PPP1R2 isoforms in human spermatozoa.

PPP1R2 PPP1R2B

7.70e-06297223506001
Pubmed

Tumour necrosis factor superfamily member 15 (Tnfsf15) facilitates lymphangiogenesis via up-regulation of Vegfr3 gene expression in lymphatic endothelial cells.

FLT4 TNFSF15

7.70e-06297226096340
Pubmed

Structural and Functional Alterations of Skeletal Muscle Microvasculature in Dystrophin-Deficient mdx Mice.

KDR DMD

7.70e-06297226193666
Pubmed

VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts.

FLT4 KDR

7.70e-06297220224550
Pubmed

VEGFR signaling during lymphatic vascular development: From progenitor cells to functional vessels.

FLT4 KDR

7.70e-06297225399804
Pubmed

Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.

FBN1 DMD

7.70e-06297217237794
Pubmed

[Expression of VEGFR-2 and VEGFR-3 in papillary renal cell carcinoma and their relationship with prognosis].

FLT4 KDR

7.70e-06297221163065
Pubmed

Combined blockade of VEGFR-2 and VEGFR-3 inhibits inflammatory lymphangiogenesis in early and middle stages.

FLT4 KDR

7.70e-06297221273538
Pubmed

Conserved signaling through vascular endothelial growth (VEGF) receptor family members in murine lymphatic endothelial cells.

FLT4 KDR

7.70e-06297221839079
Pubmed

Modulation of VEGFR-2-mediated endothelial-cell activity by VEGF-C/VEGFR-3.

FLT4 KDR

7.70e-06297212393458
Pubmed

Duchenne-like myopathy in double-mutant mdx mice expressing exaggerated mast cell activity.

FBN1 DMD

7.70e-0629727561939
Pubmed

VEGF receptor subtypes may serve as novel prognostic factors and putative indicators for anti VEGF receptor treatment response in renal cell carcinoma cases.

FLT4 KDR

7.70e-06297227837630
Pubmed

Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity.

FLT4 KDR

7.70e-06297215474514
Pubmed

B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse.

FBN1 CD22

7.70e-06297215277237
Pubmed

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

FLT4 KDR

7.70e-06297220606037
Pubmed

Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens.

FLT4 KDR

7.70e-06297212867434
Pubmed

Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis.

FLT4 KDR

7.70e-06297217210781
Pubmed

Expansion of cortical and medullary sinuses restrains lymph node hypertrophy during prolonged inflammation.

FLT4 KDR

7.70e-06297222430738
Pubmed

Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.

FLT4 KDR

7.70e-06297217535974
Pubmed

Prediction of the coding sequences of unidentified human genes. XV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.

BDP1 FBXO40 INTU ANKFY1 RALGAPA2

1.07e-0510397510574462
Pubmed

Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro.

HDAC5 CACNA2D2 WDR7 PCLO ATP10A

1.18e-051059759628581
Pubmed

The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells.

FLT4 KDR

2.31e-05397216530705
Pubmed

Early endocardial morphogenesis requires Scl/Tal1.

FLT4 KDR

2.31e-05397217722983
Pubmed

Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma.

FLT4 KDR

2.31e-05397221635552
Pubmed

Generating Vegfr3 reporter transgenic mouse expressing membrane-tagged Venus for visualization of VEGFR3 expression in vascular and lymphatic endothelial cells.

FLT4 KDR

2.31e-05397230601868
Pubmed

Interplay of vascular endothelial growth factor receptors in organ-specific vessel maintenance.

FLT4 KDR

2.31e-05397235050301
Pubmed

Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance.

FLT4 KDR

2.31e-05397224713547
Pubmed

The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®).

FLT4 KDR

2.31e-05397225340839
Pubmed

The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man.

FLT4 KDR

2.31e-05397211279005
Pubmed

Autotaxin and vascular endothelial growth factor receptor-2 and -3 are related to vascular development during the progression of chronic viral hepatitis C.

FLT4 KDR

2.31e-05397230456868
Pubmed

Not so pseudo: the evolutionary history of protein phosphatase 1 regulatory subunit 2 and related pseudogenes.

PPP1R2 PPP1R2B

2.31e-05397224195737
Pubmed

Characterization of the ZFX family of transcription factors that bind downstream of the start site of CpG island promoters.

ZFX ZNF711

2.31e-05397232406922
Pubmed

Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization.

FLT4 KDR

2.31e-05397221130043
Pubmed

Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma.

FLT4 KDR

2.31e-05397224845798
Pubmed

Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms.

FLT4 KDR

2.31e-05397229787601
Pubmed

Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B.

IGF2R DMD

2.31e-05397218276788
Pubmed

A single N-linked glycosylation site is implicated in the regulation of ligand recognition by the I-type lectins CD22 and CD33.

CD22 CD33

2.31e-0539728702538
Pubmed

Structural basis for regulation of protein phosphatase 1 by inhibitor-2.

PPP1R2 PPP1R2B

2.31e-05397217636256
Pubmed

Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis.

FLT4 KDR

2.31e-05397211574540
Pubmed

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).

FLT4 KDR

2.31e-0539729435229
Pubmed

A functional analysis of mouse models of cardiac disease through metabolic profiling.

SCN5A DMD

2.31e-05397215546876
Pubmed

Angiogenesis interactome and time course microarray data reveal the distinct activation patterns in endothelial cells.

FLT4 KDR

2.31e-05397225329517
Pubmed

Expression and localization of VEGF receptors in human fetal skeletal tissues.

FLT4 KDR

2.31e-05397223059888
Pubmed

Regulation of the cardiac sodium channel Nav1.5 by utrophin in dystrophin-deficient mice.

SCN5A DMD

2.31e-05397220952415
Pubmed

Heterogeneity in VEGFR3 levels drives lymphatic vessel hyperplasia through cell-autonomous and non-cell-autonomous mechanisms.

FLT4 KDR

2.31e-05397229615616
Pubmed

Haploinsufficiency of vascular endothelial growth factor related signaling genes is associated with tetralogy of Fallot.

FLT4 KDR

2.31e-05397230232381
Pubmed

Tubular network formation by adriamycin-resistant MCF-7 breast cancer cells is closely linked to MMP-9 and VEGFR-2/VEGFR-3 over-expressions.

FLT4 KDR

2.31e-05397222542663
Pubmed

The associations of IGF2, IGF2R and IGF2BP2 gene polymorphisms with gestational diabetes mellitus: A case-control study.

IGF2BP2 IGF2R

2.31e-05397238701040
Pubmed

Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.

FLT4 KDR

2.31e-05397225909285
Pubmed

Signaling via vascular endothelial growth factor receptors.

FLT4 KDR

2.31e-05397210579917
Pubmed

Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer.

FLT4 KDR

2.31e-05397219068081
Pubmed

Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis.

FLT4 KDR

2.31e-05397210887117
Pubmed

All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells.

FLT4 KDR

2.31e-05397214687619
Pubmed

Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma.

FLT4 KDR

2.31e-05397228718364
Pubmed

Possible genetic predisposition to lymphedema after breast cancer.

FLT4 KDR

2.31e-05397222404826
Pubmed

Expression of receptors for VEGFs on normal human thyroid follicular cells and their role in follicle formation.

FLT4 KDR

2.31e-05397221751212
Pubmed

Cardiac sodium channel Nav1.5 is regulated by a multiprotein complex composed of syntrophins and dystrophin.

SCN5A DMD

2.31e-05397216857961
Pubmed

uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis.

FLT4 KDR

2.31e-05397230518756
Pubmed

A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning.

FKBP15 DCAF8 HDAC5 GRWD1 SEPTIN9 WDR55 N4BP3 KLHL20 DOCK7 FIP1L1 DMD TRIM37

3.25e-051038971226673895
Pubmed

VEGFR3 modulates brain microvessel branching in a mouse model of 22q11.2 deletion syndrome.

FLT4 KDR

4.60e-05497236216515
Pubmed

SAP97 and dystrophin macromolecular complexes determine two pools of cardiac sodium channels Nav1.5 in cardiomyocytes.

SCN5A DMD

4.60e-05497221164104
Pubmed

[Comparative immunohistochemical evaluation of vascular endothelial growth factor and its receptors in the placental villi in gestational diabetes mellitus and type 1 diabetes].

FLT4 KDR

4.60e-05497224341227
Pubmed

Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A.

FLT4 KDR

4.60e-05497222016416
Pubmed

Cloning and characterization of human phosphatase inhibitor-2 (IPP-2) sequences.

PPP1R2 PPP1R2B

4.60e-0549727949733
Pubmed

Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.

CD22 CD33

4.60e-05497221348573
Pubmed

Phosphorylated MARCKS: a novel centrosome component that also defines a peripheral subdomain of the cortical actin cap in mouse eggs.

PRKCZ PCNT

4.60e-05497215766745
Pubmed

Differential expression of VEGF ligands and receptors in prostate cancer.

FLT4 KDR

4.60e-05497223038639
Pubmed

VEGFR3 is required for button junction formation in lymphatic vessels.

FLT4 KDR

4.60e-05497237454290
Pubmed

Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy.

FLT4 KDR

4.60e-05497228680264
Pubmed

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

FLT4 KDR

4.60e-05497219636022
Pubmed

The Relation of VEGFA, VEGFR2, VEGI, and HIF1A Genetic Variants and Their Serum Protein Levels with Breast Cancer in Egyptian Patients.

KDR TNFSF15

4.60e-05497237392242
Pubmed

Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway.

FGA DMD

4.60e-05497218593877
Pubmed

VEGFR3 does not sustain retinal angiogenesis without VEGFR2.

FLT4 KDR

4.60e-05497225561555
Pubmed

Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.

FLT4 KDR

4.60e-05497211807987
Pubmed

VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling.

FLT4 KDR

4.60e-05497228298294
Pubmed

Lymphatic ontogeny and effect of hypoplasia in developing lung.

FLT4 KDR

4.60e-05497220932899
Pubmed

O-fucosylation of thrombospondin type 1 repeats restricts epithelial to mesenchymal transition (EMT) and maintains epiblast pluripotency during mouse gastrulation.

ADGRB2 SEMA5B ADAMTS20 KDR

5.94e-057597420637190
Pubmed

Flt-1 haploinsufficiency ameliorates muscular dystrophy phenotype by developmentally increased vasculature in mdx mice.

KDR DMD

7.66e-05597220705734
Pubmed

Risk factors and genetics of atrial fibrillation.

LAMA3 SCN5A

7.66e-05597225443231
Pubmed

Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.

FLT4 KDR

7.66e-05597226735859
Pubmed

Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival.

FLT4 KDR

7.66e-05597219066962
Pubmed

Vascular endothelial growth factor-C derived from CD11b+ cells induces therapeutic improvements in a murine model of hind limb ischemia.

FLT4 KDR

7.66e-05597223219511
Pubmed

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.

FLT4 KDR

7.66e-05597219924384
Pubmed

VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis.

FLT4 KDR

7.66e-05597228438786
Pubmed

VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption.

FLT4 KDR

7.66e-05597226459520
Pubmed

Protein Phosphatase-1 Inhibitor-2 Is a Novel Memory Suppressor.

PPP1R2 PPP1R2B

7.66e-05597226558779
Pubmed

Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.

FIP1L1 KDR

7.66e-05597225411163
Pubmed

Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis.

FLT4 KDR

7.66e-05597217088944
Pubmed

RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.

FLT4 KDR

7.66e-05597221680174
Pubmed

Regulators of the protein phosphatase PP1γ2, PPP1R2, PPP1R7, and PPP1R11 are involved in epididymal sperm maturation.

PPP1R2 PPP1R2B

7.66e-05597230144392
Pubmed

Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas.

FLT4 KDR

7.66e-05597219701853
Pubmed

LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells.

DCAF8 HDAC5 GRWD1 SEPTIN9 PCLO LAMA3 DDX54 DOCK7 TRIM37

7.66e-0563997923443559
Pubmed

Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.

FBXO40 FLT4 MAP3K12 FBXO38 FBH1 PRKCZ TRIM37

8.52e-0537297722939624
Pubmed

The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices.

AMBP EMID1 LAMA3 FBN1 FGA

1.08e-0416797522159717
Pubmed

ELF a beta-spectrin is a neuronal precursor cell marker in developing mammalian brain; structure and organization of the elf/beta-G spectrin gene.

ELF1 DMD

1.15e-04697212149647
Pubmed

VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.

FLT4 KDR

1.15e-04697212810700
Pubmed

The Schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel.

FLT4 KDR

1.15e-04697225061878
InteractionPFN1 interactions

ANKFY1 HDAC5 MAP1A SEPTIN9 PCLO SPAG5 DOCK7 TMF1 BOD1L1 PRKCZ TRIM37 PCNT

3.85e-065099312int:PFN1
CytobandEnsembl 112 genes in cytogenetic band chr9q32

AMBP FKBP15 TNFSF15

1.72e-0450983chr9q32
Cytoband1q22-q23

DCAF8 RXRG

3.46e-04139821q22-q23
Cytoband1p35

ADGRB2 TMEM200B

3.46e-04139821p35
GeneFamilyCyclins|F-boxes other

FBXO40 FBXO38 FBH1

4.99e-0439723560
GeneFamilyReceptor Tyrosine Kinases|CD molecules

FLT4 ROR1 KDR

5.38e-0440723321
GeneFamilyWD repeat domain containing

DCAF8 GRWD1 WDR7 WDR55 TEP1 DCAF5

6.14e-04262726362
GeneFamilyWD repeat domain containing|DDB1 and CUL4 associated factors

DCAF8 DCAF5

2.30e-0318722498
CoexpressionMEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3

ZNF536 CACNA2D2 ROR1 ADGRB2 SGO1 N4BP3 ALS2CL ATP10A IGF2BP2 TENM4 SEMA5B SCN5A KDR PRKCZ MAP3K21

9.30e-0610749715M1941
ToppCellfacs-Trachea-18m-Endothelial-endothelial_cell_of_trachea-tracheal_endothelial_cell-tracheal_endothelial_cell_l54|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

FLT4 EMID1 N4BP3 SCN5A KDR PRKCZ TRIM37

1.79e-0718598759acaf025353405948dc34ccccf37ec5c08ea903
ToppCellfacs-Lung-nan-3m-Endothelial-Lymphatic_endothelial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CACNA1E FLT4 EMID1 SCN5A KDR C3orf80 PRKCZ

2.22e-0719198748823a97c38263f2c6e58348214f5b62773a6368
ToppCellfacs-Lung-nan-3m-Endothelial-endothelial_cell_of_lymphatic_vessel|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CACNA1E FLT4 EMID1 SCN5A KDR C3orf80 PRKCZ

2.22e-071919870eedc66e967b1837ce2c14f8c14b3c1eba868c76
ToppCellNS-moderate-d_07-13-Epithelial-FOXN4+|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)

INTU RPGRIP1L MAP1A ADGRB2 TMEM200B MINDY4

1.32e-06157986410c9d74a2085179cfb39853cb6d330fa98c9c1b
ToppCellE16.5-Endothelial-Endothelial_lymphatic|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

CACNA1E FLT4 EMID1 SCN5A KDR C3orf80

1.90e-06167986b93103a868fba63a8910bffb690a6242b9252833
ToppCellE16.5-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

CACNA1E FLT4 EMID1 SCN5A KDR C3orf80

1.90e-06167986fcd583b1efd0ac883379982ea8e6c54f2c0be268
ToppCellE16.5-Endothelial-Endothelial_lymphatic-Lymphatic_EC|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

CACNA1E FLT4 EMID1 SCN5A KDR C3orf80

1.90e-06167986f6bc63138b7239211fa5f27a8dc799b6e022c0f8
ToppCellE16.5-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC-LEC_mature|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

CACNA1E FLT4 EMID1 SCN5A KDR C3orf80

1.90e-0616798626cd8ee5e826e71eaf58d10a906543a6932fb3f9
ToppCellNS-critical-LOC-Epithelial-FOXN4+|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)

RPGRIP1L MAP1A ADGRB2 TMEM200B MINDY4 CCDC40

2.10e-06170986f6a0162bb690dbc19ff1cec64cb933744ad3b496
ToppCellLPS-antiTNF-Epithelial_alveolar-Mes-like-AT1_Progenitor|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

INTU ZNF536 ZNF711 CD22 PRKCZ MAP3K21

2.66e-06177986164ffbbf798defa3728197deb1a14b661490e525
ToppCellAdult-Epithelial-alveolar_epithelial_cell_type_1-D175|Adult / Lineage, Cell type, age group and donor

ROR1 LAMA3 ALS2CL ATP10A PRKCZ DMD

3.43e-0618598632b4e68e551d435a732f253f6ad83408c759a642
ToppCelldroplet-Lung-LUNG-30m-Endothelial-endothelial_cell_of_lymphatic_vessel|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FLT4 EMID1 N4BP3 KDR C3orf80 PRKCZ

3.54e-06186986f23f21781a758541f59c06efa7739d26a03fb478
ToppCelldroplet-Lung-LUNG-30m-Endothelial-Lymphatic_endothelial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FLT4 EMID1 N4BP3 KDR C3orf80 PRKCZ

3.54e-061869860de87109da9324c597fadf2eb782f0f158afe832
ToppCellfacs-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l20-23|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

GRWD1 ROR1 TENM4 SCN5A ADAMTS20 DMD

3.65e-0618798669b47f00598d647e2a99427ebddf42c339428e47
ToppCellCOVID_vent-Myeloid-Monocytic-SC_&_Eosinophil|COVID_vent / Disease condition, Lineage, Cell class and subclass

MAP1A EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

3.88e-061899862157a2d40613f7d5ce2e7dbd266df441e449cdaf
ToppCellfacs-Lung-3m-Endothelial-lymphatic_endothelial|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

FLT4 EMID1 SCN5A KDR C3orf80 PRKCZ

4.00e-06190986a1514d2186eb4fe569971ab22dc0c17d353fb94a
ToppCellNS-moderate-d_16-33-Epithelial-FOXN4+|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)

INTU RPGRIP1L ADGRB2 TMEM200B MINDY4 PCNT

4.00e-06190986250ca4a605c1cccd77d23383e4fe6f91cf3609ba
ToppCellfacs-Lung-3m-Endothelial-lymphatic_endothelial-lymphatic_endothelial_cell|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

FLT4 EMID1 SCN5A KDR C3orf80 PRKCZ

4.00e-061909860bb954a94317cfc742b9b6221bb80f8baa6d3ff1
ToppCellfacs-Lung-3m-Endothelial-lymphatic_endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

FLT4 EMID1 SCN5A KDR C3orf80 PRKCZ

4.00e-0619098626e2237f65cb43723c5da853831b40df2982d6e4
ToppCell3'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.2.2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

INTU RPGRIP1L IGF2BP2 DMD DTHD1 CCDC40

4.92e-0619798674a2c6cb8fcfe53dd9a2b36492a16c58f38e51c9
ToppCellEndothelial-G|World / shred on cell class and cell subclass (v4)

FLT4 EMID1 TMEM200B KDR C3orf80

8.11e-061249854b72809463f2986b7d1b7ab9de633ac4d7854a92
ToppCellPND03-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FLT4 EMID1 SCN5A KDR C3orf80

3.22e-05165985347b59aa625a8a960828b8620824d8ac48990e07
ToppCellPND03-Endothelial-Endothelial_lymphatic-Lymphatic_EC|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FLT4 EMID1 SCN5A KDR C3orf80

3.22e-05165985507c89ece0a336b8e9c65b79889a714e17ddca27
ToppCellPND03-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC-LEC_mature|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FLT4 EMID1 SCN5A KDR C3orf80

3.22e-0516598539a25be081a5d59c7cf107a997d352793d5025fb
ToppCellPND03-Endothelial-Endothelial_lymphatic|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FLT4 EMID1 SCN5A KDR C3orf80

3.22e-051659851890f9c33b0c5b381d57f97042da2610a093a6de
ToppCellremission-HSPC|World / disease stage, cell group and cell class

MAP1A EMID1 ZNF711 IGF2BP2 FBN1

3.31e-05166985d269ee6f7adb55b05dcb5eaea96629ccb0b2d6e3
ToppCelldroplet-Lung-18m-Hematologic-lymphocytic-Zbtb32+_B_cell-Zbtb32+_B_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

CACNA1E ZNF536 TENM4 CD22 PRKCZ

3.41e-051679853c3e1c31aacca48099693aea2efdfa22fc0e4af4
ToppCellCOVID-19-kidney-Lymphatic_EC|kidney / Disease (COVID-19 only), tissue and cell type

FLT4 RALGAPA2 PPP1R2 FBN1 KDR

3.41e-0516798597d0fea1f41c1c00e36d9b5c4c1f0dd85087056f
ToppCelldroplet-Lung-18m-Hematologic-lymphocytic-Zbtb32+_B_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

CACNA1E ZNF536 TENM4 CD22 PRKCZ

3.41e-0516798577a4d7ce44847c76074d4f5340d61b398fe43e6c
ToppCellmild_COVID-19-HSPC|mild_COVID-19 / disease group, cell group and cell class (v2)

EMID1 LAMA3 ZNF711 FBN1 C3orf80

3.51e-0516898590b33962adb77d8326dee403712118398b4d1315
ToppCellPND01-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC-LEC_mature|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FLT4 EMID1 N4BP3 KDR C3orf80

3.61e-05169985f077e39e41fffe7672541f5b72b80faaf56c597c
ToppCell390C-Epithelial_cells-Epithelial-I_(AT1)|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)

ANKFY1 LAMA3 ATP10A PRSS53 TRIM37

3.61e-05169985665b958f4a720ca369a8a0abc7fbe8b6e13c8ce5
ToppCelldroplet-Lung-30m-Hematologic-Lymphocytic_NK_ILC-natural_killer_cell-proliferating_NK|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

ROR1 EMID1 ADGRB2 SGO1 SPAG5

3.61e-05169985822e5b6c1e55e196e6d2a38bf183fd220c45703e
ToppCell390C-Epithelial_cells-Epithelial-I_(AT1)-|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)

ANKFY1 LAMA3 ATP10A PRSS53 TRIM37

3.61e-051699856614c9851537e4c21b1e45ff0cc3bad07ef9d034
ToppCellPND01-Endothelial-Endothelial_lymphatic-Lymphatic_EC|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FLT4 EMID1 N4BP3 KDR C3orf80

3.71e-0517098535e3945d8a540a3e2cec1b559316265aaad023d1
ToppCellPND01-Endothelial-Endothelial_lymphatic|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FLT4 EMID1 N4BP3 KDR C3orf80

3.71e-051709850ea625abaa25bab93b70b7000e8f90d5c0f9a0fb
ToppCellmild_COVID-19-HSPC|World / disease group, cell group and cell class (v2)

EMID1 LAMA3 ZNF711 FBN1 C3orf80

3.71e-0517098585c476e0bc496445e868a88849960598d97bdea2
ToppCellPND01-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FLT4 EMID1 N4BP3 KDR C3orf80

3.71e-051709850b5ddc7d452db0a389927a367914f7d257703f7e
ToppCellPBMC-Convalescent-Hematopoietic-HSPC-HSPC|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

MAP1A EMID1 ZNF711 IGF2BP2 FBN1

3.82e-051719852031797d579ce373921affad70da6e50eec13664
ToppCellremission-HSPC|remission / disease stage, cell group and cell class

MAP1A EMID1 ZNF711 IGF2BP2 FBN1

3.82e-0517198541b424e58470a2fc25632aea50a37c7c5ea17645
ToppCellPBMC-Convalescent-Hematopoietic-HSPC-HSPC-|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

MAP1A EMID1 ZNF711 IGF2BP2 FBN1

3.82e-05171985a4e13b304ef414722ffdc06560deeab41785e956
ToppCellPBMC-Convalescent-Hematopoietic-HSPC|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

MAP1A EMID1 ZNF711 IGF2BP2 FBN1

3.82e-05171985172db31a37b72fb87fe5f0f79da51866b90dd1ad
ToppCellPBMC-Convalescent-Hematopoietic-HSPC-HSPC-|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

MAP1A EMID1 ZNF711 IGF2BP2 FBN1

3.93e-051729858fd3db757d54949bd583d5f0eadf63a32342cb9d
ToppCellPBMC-Convalescent-Hematopoietic-HSPC|Convalescent / Location, Disease Group, Cell group, Cell class (2021.03.09)

MAP1A EMID1 ZNF711 IGF2BP2 FBN1

3.93e-05172985da78f7a71b7f05c5c484c9ed19ba37c55d35e870
ToppCellPBMC-Convalescent-Hematopoietic-HSPC-HSPC|Convalescent / Location, Disease Group, Cell group, Cell class (2021.03.09)

MAP1A EMID1 ZNF711 IGF2BP2 FBN1

3.93e-05172985382cb5fea099110eb026a8bba6cf4c28763ea52f
ToppCelldroplet-Heart-HEART-1m-Endothelial-leukocyte|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FLT4 EMID1 IGF2BP2 C3orf80 PRKCZ

4.03e-051739859dc7746a84f0e268a7c061e1bbcd5e31903034dc
ToppCellAT1-AT2_cells-Donor_06|World / lung cells shred on cell class, cell subclass, sample id

CACNA2D2 ROR1 LAMA3 ALS2CL PRKCZ

4.26e-05175985bdd85ba280648a0283c1984662a34c7b840f64dd
ToppCellfacs-Lung-Endomucin-24m-Endothelial-endothelial_cell_of_lymphatic_vessel|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FLT4 EMID1 SCN5A KDR PRKCZ

4.38e-05176985057d2759fdc67176c25802b57a78064d8cc93205
ToppCellfacs-Lung-Endomucin-24m-Endothelial-Lymphatic_endothelial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FLT4 EMID1 SCN5A KDR PRKCZ

4.38e-05176985b81e5d23b31cefc8d374ef403e21acc390c14a80
ToppCellP28-Endothelial-lymphatic_endothelial_cell|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

FLT4 EMID1 SCN5A C3orf80 PRKCZ

4.50e-051779856e330aa3c87fd640526b746a9deb3b2250d2518c
ToppCellP28-Endothelial-lymphatic_endothelial_cell-endothelial_cell_of_lymphatic_vessel|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

FLT4 EMID1 SCN5A C3orf80 PRKCZ

4.50e-05177985e96a7e4544710aaab8bd2800ecff9667880a8bf4
ToppCellfacs-Lung-EPCAM-3m-Mesenchymal-adventitial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

MAP1A ADGRB2 ATP10A FBN1 KCNG4

4.62e-0517898527497dbfcf9bb4dd0bf7caa0bd78c7e85f5c18ee
ToppCellfacs-Lung-EPCAM-3m-Mesenchymal-Adventitial_Fibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

MAP1A ADGRB2 ATP10A FBN1 KCNG4

4.62e-05178985d348a9550db940d204706529759dc51e30506b5f
ToppCellPBMC-Mild-Hematopoietic-HSPC-HSPC-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

4.75e-051799854bb2debfc9e9f258cd38e797ef160bd440aad6af
ToppCellPND01-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC-LEC_G2M|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FLT4 EMID1 SGO1 C3orf80 PRKCZ

4.75e-05179985df4d0b2fe47d2c7def729b3217cb01ced01495ff
ToppCellPBMC-Mild-Hematopoietic-HSPC|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

4.75e-051799852f690f933bf6b99abeb31766e0b22bdbe36c1ba0
ToppCelldroplet-Heart-HEART-1m-Mesenchymal-coronary_vascular_endothelial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CABLES2 HDAC5 EMID1 ALS2CL IGF2BP2

4.75e-05179985dd94ebe69ade6f51b94058abe066216f0de9feda
ToppCellPBMC-Mild-Hematopoietic-HSPC-HSPC|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

4.75e-051799853e2c937369b8190fd5d5a31689d029e6e89fb5e2
ToppCellMid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1_SST_CXCL14|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

ZNF536 EMID1 RXRG SCN5A ANKFN1

4.87e-05180985b6efdb4d319ef6f87f559acd974e5a71b06a2322
ToppCellPBMC-Mild-Hematopoietic-HSPC-HSPC-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

5.00e-05181985e7f7b519c2a01c15f26df11ec9b434c0d1630c7a
ToppCellPBMC-Mild-Hematopoietic-HSPC-HSPC|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)

EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

5.00e-0518198554a19cf6a3b752e2391feb8b316bebee0e602d17
ToppCellPBMC-Mild-Hematopoietic-HSPC|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)

EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

5.00e-051819855b84625b1d3737708001b64f6da9360330d39a27
ToppCelldroplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Mesenchymal-coronary_vascular_endothelial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CABLES2 FLT4 LAMA3 ZNF711 DDX54

5.00e-05181985709e9c7a60d5f98635b99895ce30bb87a9f7376d
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

FLT4 PPP1R2 FBN1 KCNG4 KDR

5.13e-0518298541b070085edba7a58b81c20aa4942d06f745acf8
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex-lymphatic_endothelial_cell_of_renal_cortex|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

FLT4 PPP1R2 FBN1 KCNG4 KDR

5.13e-051829855e9a67b2de0daa4fdc344b10a857d8a901ad810e
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Endothelial-lymphatic_endothelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

FLT4 PPP1R2 FBN1 KCNG4 KDR

5.13e-05182985b0fe042c71d6ab8c75abd7ba9d2de00b72d01c0c
ToppCellCOVID-19-lung-AT1|COVID-19 / Disease (COVID-19 only), tissue and cell type

ROR1 LAMA3 ALS2CL ATP10A PRKCZ

5.27e-051839857b1a385ed54f93bfe85bf0c162e42d05d516b45c
ToppCellP03-Endothelial-lymphatic_endothelial_cell-endothelial_cell_of_lymphatic_vessel|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

FLT4 EMID1 SCN5A C3orf80 PRKCZ

5.27e-0518398589727b4f65949ed2dce9d2e0228c79fe4280230c
ToppCellP03-Endothelial-lymphatic_endothelial_cell|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

FLT4 EMID1 SCN5A C3orf80 PRKCZ

5.27e-05183985113e6d8d4bb271be984af06cd6c22b180425dcfc
ToppCellAT1-AT2_cells-Donor_02|World / lung cells shred on cell class, cell subclass, sample id

CACNA2D2 PCLO ROR1 LAMA3 ALS2CL

5.27e-051839856821dca076318115d360ff426eb1218cfe104063
ToppCellPBMC-Severe-Hematopoietic-HSPC|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

5.41e-05184985a6169613c6493b947a176493f542368bfa935dab
ToppCellPBMC-Severe-Hematopoietic-HSPC-HSPC|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

5.41e-0518498551d0447699e3b8f01abbde83f26b748bc9f3c723
ToppCellPBMC-Severe-Hematopoietic-HSPC-HSPC-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

5.41e-05184985f7b0bb45a9055ab34e98b251217f6ec38c75ca22
ToppCellPosterior_cortex-Neuronal-Excitatory|Posterior_cortex / BrainAtlas - Mouse McCarroll V32

CACNA1E HIVEP2 ADGRB2 KLF9 C3orf80

5.41e-0518498525ccf08a8a26d7e7827b6357f33a53aaf423577d
ToppCellAdult-Epithelial-alveolar_epithelial_cell_type_1-D122|Adult / Lineage, Cell type, age group and donor

ROR1 LAMA3 ALS2CL PRKCZ DMD

5.41e-05184985561592edc3083fad41b91811151b442207c65dd9
ToppCellCOVID-19_Moderate-HSPC|World / disease group, cell group and cell class

EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

5.41e-05184985ccc93babe1fcdeb66b78e1d8414357877a7c45bd
ToppCellPBMC-Severe-Hematopoietic-HSPC-HSPC|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

5.41e-05184985cc01c19180861f491a8dc16d60fabd1215fc4525
ToppCelldroplet-Lung-LUNG-30m-Myeloid-Proliferating_Alveolar_Macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PCLO SGO1 KRT79 ATP10A NECTIN4

5.41e-0518498516aa8e88bdd51b1d132d5cf33c29963b384a8bae
ToppCellPBMC-Severe-Hematopoietic-HSPC-HSPC-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

5.41e-05184985492c680f0769ba4e651d09c2e8e5d5d271ed08aa
ToppCellPBMC-Severe-Hematopoietic-HSPC|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)

EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

5.41e-0518498526edbf84216538b80f1ffcc079ee6e385a71fbf9
ToppCelldroplet-Lung-nan-21m-Endothelial-endothelial_cell_of_lymphatic_vessel|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CACNA1E FLT4 EMID1 C3orf80 PRKCZ

5.55e-051859853a4ae836e882e8d29eb0a2dfab5677f10f2d365f
ToppCellControl-Epithelial-ATI|World / Disease state, Lineage and Cell class

CACNA2D2 ROR1 LAMA3 ALS2CL PRKCZ

5.55e-051859850563d5042bb96ecce8446fbf26d05ef7a45e23c5
ToppCellCOVID-19_Moderate-HSPC|COVID-19_Moderate / disease group, cell group and cell class

EMID1 ZNF711 IGF2BP2 FBN1 C3orf80

5.55e-05185985cacc6ab5f26f6c803894567fb838ea06eaa7efe5
ToppCelldroplet-Lung-nan-21m-Endothelial-Lymphatic_endothelial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CACNA1E FLT4 EMID1 C3orf80 PRKCZ

5.55e-05185985224f0b022c21dd40bf1f7503f00b3107ef958975
ToppCellPCW_13-14-Epithelial-Epithelial_airway-epi_proximal_progenitor1_(6)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung

PCLO LAMA3 PRKCZ DMD MAP3K21

5.99e-051889850d86044bc340e3efb90d0022dd299873639d831c
ToppCellFetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

SEPTIN9 ROR1 LAMA3 IGF2BP2 PRKCZ

5.99e-0518898543a3a59f92ad93509d4166bd025aed0b1b39a008
ToppCellfacs-Trachea-nan-3m-Mesenchymal-smooth_muscle_cell_of_trachea|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ZNF536 ROR1 TENM4 ADAMTS20 DMD

5.99e-05188985794fc1d9a726945c42f7eac221eed938309b47a9
ToppCellPCW_10-12-Epithelial-Epithelial_airway-epi_proximal_progenitor1_(6)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung

PCLO LAMA3 PRKCZ DMD MAP3K21

5.99e-05188985beb2df2332a46cc81b10e8e29fc9829020111f03
ToppCellCOVID-19_Severe-HSPC|World / disease group, cell group and cell class

PCLO EMID1 ZNF711 FBN1 C3orf80

6.14e-05189985555c0b13f1508b9e3712b36d77144e73e828bc76
ToppCellPCW_07-8.5-Epithelial-Epithelial_airway-epi_proximal_progenitor1_(6)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung

PCLO LAMA3 NECTIN4 PRKCZ DMD

6.14e-051899857659c7bbd58ee959a159294fb8d17317bbcc5681
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

FLT4 RALGAPA2 PPP1R2 FBN1 KDR

6.30e-05190985876bd2eb9ed2624cb23bdcf6b989e4fa34d099e3
ToppCellPCW_07-8.5-Epithelial-Epithelial_airway-epi_intermediate_(1)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung

PCLO LAMA3 PRKCZ DMD MAP3K21

6.30e-05190985c95032bb3ee2b3d40fdf48016acb46d6f78a48a6
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex-lymphatic_endothelial_cell_of_renal_cortex|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

FLT4 RALGAPA2 PPP1R2 FBN1 KDR

6.30e-05190985be9f36127028f52ca5fc1b32ba15a6c26aad69ac
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

FLT4 RALGAPA2 PPP1R2 FBN1 KDR

6.30e-0519098509a8855901c3c9332dbaab3e40166485b696d0f1
ToppCellLA-03._Atrial_Cardiomyocyte|LA / Chamber and Cluster_Paper

CACNA1E FBXO40 ROR1 SCN5A DMD

6.45e-051919855d1b674eb7703830b7ce8bbeac3363cabd0e6ae9
ToppCellfacs-Brain_Non-Myeloid-Cortex-24m-Neuronal|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CACNA1E HIVEP2 PCLO ADGRB2 TENM4

6.78e-05193985be28070c049e7cb68bcd54f582226eb2f5e4bc1c
ToppCell10x_3'_v2v3-Non-neoplastic-Endothelial-Endothelial_mature-Endo_arterial-A|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

FLT4 DCAF8 N4BP3 ATP10A KDR

6.78e-051939853f8280ef849d95b2fcea5e6824b95a07febc96d0
ToppCellCOVID-19-Fibroblasts-Other_FB|COVID-19 / group, cell type (main and fine annotations)

ZNF536 ROR1 FBN1 TENM4 DMD

6.78e-05193985e6b75be08e33c1de079fb5c02f0b4468128b369c
ToppCellfacs-Brain_Non-Myeloid-Cortex-24m-Neuronal-nan|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CACNA1E HIVEP2 PCLO ADGRB2 TENM4

6.78e-051939850c652ebe22ce5d2927599dd97ef1920547858395
ToppCellfacs-Brain_Non-Myeloid-Cortex-24m-Neuronal-neuron|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CACNA1E HIVEP2 PCLO ADGRB2 TENM4

6.78e-051939858689a70a33a7c3823dc647d41ac0160e7c3ae396
DrugHydralazine hydrochloride [304-20-1]; Down 200; 20.4uM; MCF7; HT_HG-U133A

FKBP15 ANKFY1 NCAPH2 TEP1 ALS2CL KLHL20 ZFX KLF9 DDX54 FUT6

1.06e-0819298104746_DN
DrugPF-00875133-00 [351322-64-0]; Down 200; 10uM; PC3; HT_HG-U133A

AMBP FLT4 SEPTIN9 NCAPH2 ALS2CL ZNF711 TENM4 CD22

2.12e-061969885928_DN
Drugpioglitazone HCl; Down 200; 10uM; MCF7; HT_HG-U133A

PAPPA2 SETD1A HIVEP2 DCAF8 NCAPH2 ALS2CL ZFX GYG2

2.20e-061979887523_DN
DrugNitrarine dihydrochloride [20069-05-0]; Down 200; 10.6uM; MCF7; HT_HG-U133A

FKBP15 RPGRIP1L NCAPH2 MAP3K12 KLHL20 ZFX TIGD6 GYG2

2.29e-061989884705_DN
DrugBeta-sistosterol [83-46-5]; Up 200; 9.6uM; MCF7; HT_HG-U133A

RPGRIP1L MAP1A SEPTIN9 ALS2CL KLHL20 ZFX EHBP1L1 ZNF304

2.29e-061989887332_UP
DrugIsocarboxazid [59-63-2]; Down 200; 17.2uM; PC3; HT_HG-U133A

SETD1A DCAF8 ROR1 NCAPH2 MAP3K12 TIGD6 CD22 CCDC40

2.38e-061999883684_DN
Drugindecainide

AMBP SCN5A

1.83e-052982CID000052194
Drugpioglitazone HCl; Down 200; 10uM; PC3; HT_HG-U133A

CACNA2D2 SEPTIN9 ALS2CL KLHL20 FBN1 CD22 TNFSF15

1.97e-051929875930_DN
DrugGuanabenz acetate [23256-50-0]; Down 200; 13.8uM; PC3; HG-U133A

PAPPA2 HIVEP2 DCAF8 PCLO ALS2CL FBN1 FUT6

2.04e-051939871961_DN
DrugDecamethonium bromide [541-22-0]; Down 200; 9.6uM; MCF7; HT_HG-U133A

PAPPA2 HIVEP2 RPGRIP1L MAP1A CACNA2D2 SEPTIN9 NCAPH2

2.10e-051949874174_DN
DrugClozapine [5786-21-0]; Up 200; 12.2uM; MCF7; HT_HG-U133A

PAPPA2 SETD1A HDAC5 NCAPH2 N4BP3 EHBP1L1 KDR

2.17e-051959875265_UP
Drug(-)-depudecin; Up 200; 1uM; MCF7; HT_HG-U133A_EA

FKBP15 MAP1A SEPTIN9 EMID1 MAP3K12 KLF9 GYG2

2.17e-05195987874_UP
DrugAminopurine, 6-benzyl [1214-39-7]; Down 200; 17.8uM; MCF7; HT_HG-U133A

HIVEP2 SEPTIN9 EMID1 NCAPH2 N4BP3 MAP3K12 EHBP1L1

2.17e-051959872313_DN
DrugEsculetin [305-01-1]; Down 200; 22.4uM; HL60; HT_HG-U133A

PAPPA2 NCAPH2 MAP3K12 TIGD6 IGF2BP2 CD22 PRKCZ

2.17e-051959873120_DN
DrugCimetidine [51481-61-9]; Up 200; 15.8uM; PC3; HT_HG-U133A

PAPPA2 ADGRB2 NCAPH2 ATP10A CD33 TNFSF15 CCDC40

2.17e-051959874063_UP
DrugPrednisolone [50-24-8]; Up 200; 11uM; MCF7; HT_HG-U133A

WDR7 NCAPH2 N4BP3 MAP3K12 FBXO38 KLF9 FUT6

2.25e-051969877424_UP
DrugEpivincamine [6835-99-0]; Down 200; 11.2uM; MCF7; HT_HG-U133A

ANKFY1 HIVEP2 RPGRIP1L WDR7 N4BP3 EHBP1L1 GYG2

2.25e-051969872775_DN
DrugIoversol [87771-40-2]; Down 200; 5uM; MCF7; HT_HG-U133A

HDAC5 EMID1 WDR55 NCAPH2 MAP3K12 DDX54 GYG2

2.32e-051979873365_DN
DrugPyrithyldione [77-04-3]; Up 200; 24uM; MCF7; HT_HG-U133A

EMID1 NCAPH2 ALS2CL ATP10A TIGD6 EHBP1L1 FBN1

2.32e-051979876801_UP
DrugFlavoxate hydrochloride [3717-88-2]; Up 200; 9.4uM; MCF7; HT_HG-U133A

FLT4 HIVEP2 ADGRB2 ALS2CL ATP10A IRF9 FUT6

2.32e-051979877405_UP
DrugMethyldopate hydrochloride [2508-79-4]; Up 200; 14.6uM; MCF7; HT_HG-U133A

HIVEP2 MAP1A ALS2CL KLHL20 TIGD6 EHBP1L1 FGA

2.32e-051979877360_UP
Drugalpha-Santonin [481-06-1]; Down 200; 16.2uM; MCF7; HT_HG-U133A

HIVEP2 PCLO WDR55 NCAPH2 TEP1 EHBP1L1 GYG2

2.32e-051979873877_DN
DrugClindamycin hydrochloride [21462-39-5]; Up 200; 8.6uM; PC3; HT_HG-U133A

SETD1A ROR1 TEP1 KLHL20 TENM4 CD33 CCDC40

2.40e-051989872057_UP
Drug5286656; Down 200; 50uM; MCF7; HT_HG-U133A_EA

SETD1A DCAF8 WDR7 ALS2CL LPIN2 GYG2 ELF1

2.40e-05198987889_DN
DrugMebendazole [31431-39-7]; Down 200; 13.6uM; PC3; HT_HG-U133A

DCAF8 MAP1A NCAPH2 MAP3K12 IRF9 EHBP1L1 DDX54

2.40e-051989877370_DN
DrugAzlocillin sodium salt [37091-65-9]; Up 200; 8.2uM; MCF7; HT_HG-U133A

PAPPA2 FBXO40 WDR55 TIGD6 EHBP1L1 LPIN2 GYG2

2.48e-051999876262_UP
DrugTinidazole [19387-91-8]; Down 200; 16.2uM; MCF7; HT_HG-U133A

ANKFY1 N4BP3 ZFX IRF9 EHBP1L1 CD22 GYG2

2.48e-051999873430_DN
DrugAzaguanine-8 [134-58-7]; Up 200; 26.2uM; MCF7; HT_HG-U133A

HIVEP2 WDR55 ALS2CL EHBP1L1 KLF9 GYG2 CCDC40

2.56e-052009877444_UP
Drugiodine monochloride

INTU FGA TRIM37

9.72e-0521983CID000024640
DrugT67416

FLT4 KDR

1.09e-044982CID000956683
Drugtrichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A

ANKFY1 HIVEP2 TEP1 ZFX ZNF711 ELF1

1.30e-041809865981_DN
DrugNortriptyline hydrochloride [894-71-3]; Up 200; 13.4uM; MCF7; HT_HG-U133A

FLT4 MAP3K12 IRF9 EHBP1L1 KLF9 LPIN2

1.38e-041829867422_UP
Drugtrichostatin A; Down 200; 0.1uM; PC3; HG-U133A

HIVEP2 DCAF8 FAF1 ZFX IRF9 CD22

1.59e-04187986448_DN
DrugDilazep dihydrochloride [20153-98-4]; Up 200; 6uM; MCF7; HT_HG-U133A

FBXO40 CACNA2D2 PCLO KLHL20 FBN1 ZNF304

1.69e-041899864688_UP
Drug17-AAG; Up 200; 1uM; PC3; HT_HG-U133A

PAPPA2 CACNA2D2 N4BP3 KLHL20 CD22 CCDC40

1.69e-041899864450_UP
DrugPepstatin A [26305-03-3]; Up 200; 5.8uM; HL60; HT_HG-U133A

SETD1A SEPTIN9 TEP1 IGF2BP2 PRKCZ FUT6

1.79e-041919861328_UP
Drugchalcopyrite

SPAG5 TRIM37

1.82e-045982CID003081378
Drugcarmustine; Up 200; 100uM; MCF7; HT_HG-U133A

WDR7 NCAPH2 KLHL20 ZFX TMF1 FIP1L1

1.84e-041929866914_UP
DrugHomochlorcyclizine dihydrochloride [1982-36-1]; Up 200; 10.4uM; MCF7; HT_HG-U133A

FBXO40 SEPTIN9 EMID1 LAMA3 TIGD6 EHBP1L1

1.89e-041939865998_UP
DrugDizocilpine maleate [77086-22-7]; Up 200; 11.8uM; MCF7; HT_HG-U133A

MAP1A CACNA2D2 TEP1 ALS2CL MAP3K12 TIGD6

1.89e-041939866223_UP
Drug2-propylpentanoic acid; Up 200; 200uM; HL60; HT_HG-U133A

PAPPA2 FLT4 SEPTIN9 EMID1 IGF2BP2 FUT6

1.95e-041949866173_UP
DrugTenoxicam [59804-37-4]; Up 200; 11.8uM; MCF7; HT_HG-U133A

AMBP PAPPA2 WDR55 SCN5A DMD ZNF304

1.95e-041949864182_UP
DrugMethocarbamol [532-03-6]; Down 200; 16.6uM; MCF7; HT_HG-U133A

DCAF8 NCAPH2 N4BP3 MAP3K12 KLF9 LPIN2

2.00e-041959867467_DN
DrugTrimeprazine tartrate [4330-99-8]; Up 200; 5.4uM; MCF7; HT_HG-U133A

SETD1A DCAF8 HDAC5 WDR55 ZFX GYG2

2.00e-041959863478_UP
DrugPiracetam [7491-74-9]; Up 200; 28.2uM; MCF7; HT_HG-U133A

EMID1 WDR55 CD22 ADAMTS20 GYG2 FUT6

2.00e-041959862861_UP
DrugButoconazole nitrate [32872-77-1]; Down 200; 8.4uM; MCF7; HT_HG-U133A

SETD1A FKBP15 GRWD1 CACNA2D2 FBXO38 ELF1

2.00e-041959863288_DN
Drughaloperidol; Down 200; 10uM; MCF7; HT_HG-U133A

FLT4 HDAC5 SEPTIN9 TEP1 ALS2CL ZFX

2.00e-041959865241_DN
DrugSulfamerazine [127-79-7]; Down 200; 15.2uM; PC3; HT_HG-U133A

FKBP15 CACNA2D2 ADGRB2 FBXO38 EHBP1L1 CD22

2.00e-041959863718_DN
DrugProbucol [23288-49-5]; Down 200; 7.8uM; MCF7; HT_HG-U133A

NCAPH2 MAP3K12 KLHL20 ZNF711 GYG2 FUT6

2.00e-041959865626_DN
DrugDroperidol [548-73-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A

ANKFY1 DCAF8 EMID1 NCAPH2 KLF9 LPIN2

2.06e-041969862645_DN
DrugGossypol [303-45-7]; Down 200; 7.8uM; PC3; HT_HG-U133A

PAPPA2 ADGRB2 WDR55 NCAPH2 ATP10A KLHL20

2.06e-041969863740_DN
DrugAtractyloside potassium salt [102130-43-8]; Up 200; 5uM; MCF7; HT_HG-U133A

ANKFY1 HIVEP2 DCAF8 ALS2CL MAP3K12 KLF9

2.06e-041969863435_UP
DrugIsopyrin hydrochloride [18342-39-7]; Down 200; 14.2uM; HL60; HT_HG-U133A

FBXO40 MAP1A SEPTIN9 NCAPH2 ALS2CL IGF2BP2

2.06e-041969862534_DN
DrugPHA-00851261E [724719-49-7]; Down 200; 1uM; MCF7; HT_HG-U133A

LAMA3 MAP3K12 CD22 DDX54 GYG2 FUT6

2.06e-041969863857_DN
DrugBeclomethasone dipropionate [5534-09-8]; Down 200; 7.6uM; MCF7; HT_HG-U133A

FLT4 RPGRIP1L EMID1 WDR55 IRF9 FIP1L1

2.06e-041969864403_DN
DrugAztreonam [78110-38-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A

HDAC5 SEPTIN9 TEP1 KLHL20 FGA DMD

2.06e-041969862282_UP
DrugGSK-3 Inhibitor IX; Up 200; 0.5uM; PC3; HT_HG-U133A

SETD1A DCAF8 NCAPH2 TEP1 MAP3K12 DDX54

2.06e-041969866559_UP
DrugEthotoin [86-35-1]; Down 200; 19.6uM; MCF7; HT_HG-U133A

PAPPA2 TEP1 EHBP1L1 KLF9 LPIN2 TMF1

2.06e-041969863892_DN
Drug6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; MCF7; HT_HG-U133A

FLT4 DCAF8 TEP1 ALS2CL FIP1L1 GYG2

2.06e-041969866813_DN
DrugMethacycline hydrochloride [3963-95-9]; Down 200; 8.4uM; MCF7; HT_HG-U133A

DCAF8 CACNA2D2 NCAPH2 ZFX EHBP1L1 DDX54

2.06e-041969864143_DN
DrugPropylthiouracil [51-52-5]; Up 200; 23.4uM; MCF7; HT_HG-U133A

WDR55 TEP1 ALS2CL EHBP1L1 TENM4 CD22

2.06e-041969862837_UP
DrugLobeline alpha (-) hydrochoride [134-63-4]; Up 200; 10.6uM; HL60; HG-U133A

MAP1A ADGRB2 N4BP3 SCN5A DDX54 CCDC40

2.06e-041969861770_UP
DrugQuinic acid [86-68-0]; Up 200; 19.6uM; MCF7; HT_HG-U133A

SETD1A NCAPH2 TEP1 ALS2CL ZFX CCDC40

2.11e-041979863540_UP
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A

PAPPA2 SETD1A SEPTIN9 NCAPH2 EHBP1L1 PRKCZ

2.11e-041979866143_DN
DrugKynurenine, 3-hydroxy (R,S) [2147-61-7]; Up 200; 17.8uM; MCF7; HT_HG-U133A

SETD1A NCAPH2 IRF9 SCN5A CCDC40 ZNF304

2.11e-041979865276_UP
DrugAcetaminophen [103-90-2]; Down 200; 26.4uM; MCF7; HT_HG-U133A

HIVEP2 HDAC5 WDR55 N4BP3 TEP1 KLHL20

2.11e-041979863364_DN
DrugPhentolamine hydrochloride [73-05-2]; Up 200; 12.6uM; HL60; HT_HG-U133A

ANKFY1 NCAPH2 ALS2CL IGF2BP2 EHBP1L1 FBN1

2.11e-041979862362_UP
DrugIsoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride; Down 200; 16.4uM; HL60; HT_HG-U133A

SETD1A FLT4 HIVEP2 MAP3K12 ZFX TIGD6

2.11e-041979862463_DN
DrugCP-645525-01 [287190-82-3]; Down 200; 10uM; MCF7; HT_HG-U133A

PAPPA2 EMID1 NCAPH2 ZFX GYG2 CCDC40

2.11e-041979867522_DN
DrugHexestrol [84-16-2]; Down 200; 14.8uM; MCF7; HT_HG-U133A

SETD1A ALS2CL KLHL20 ZFX EHBP1L1 GYG2

2.11e-041979866077_DN
DrugLY 294002; Down 200; 0.1uM; HL60; HT_HG-U133A

HDAC5 NCAPH2 ZFX EHBP1L1 KLF9 PRKCZ

2.11e-041979861157_DN
DrugCP-319743 [172078-87-4]; Down 200; 10uM; MCF7; HT_HG-U133A

PAPPA2 SETD1A HDAC5 CACNA2D2 EHBP1L1 FUT6

2.11e-041979867486_DN
DrugBrinzolamide [138890-62-7]; Up 200; 10.4uM; MCF7; HT_HG-U133A

CACNA2D2 WDR55 ALS2CL IRF9 FUT6 ZNF304

2.11e-041979865016_UP
DrugNiridazole [61-57-4]; Down 200; 18.6uM; MCF7; HT_HG-U133A

SETD1A FKBP15 SEPTIN9 LAMA3 TEP1 EHBP1L1

2.11e-041979863301_DN
DrugCanrenoic acid potassium salt [2181-04-6]; Down 200; 10uM; MCF7; HT_HG-U133A

FLT4 RPGRIP1L DCAF8 EMID1 LAMA3 N4BP3

2.11e-041979862228_DN
DrugMexiletine hydrochloride [5370-01-4]; Down 200; 18.6uM; MCF7; HT_HG-U133A

SETD1A FLT4 ANKFY1 HDAC5 CACNA2D2 NCAPH2

2.11e-041979862324_DN
DrugCefuroxime sodium salt [56238-63-2]; Down 200; 9uM; HL60; HT_HG-U133A

FLT4 NCAPH2 TEP1 ALS2CL DDX54 FIP1L1

2.11e-041979862526_DN
Drug5211181; Down 200; 12uM; MCF7; HT_HG-U133A_EA

ANKFY1 DCAF8 SEPTIN9 ZFX TIGD6 FBXO38

2.11e-04197986834_DN
DrugArcaine sulfate [14923-17-2]; Down 200; 14.8uM; MCF7; HT_HG-U133A

PCLO NCAPH2 MAP3K12 KLHL20 TIGD6 ZNF304

2.11e-041979864974_DN
DrugIsopropamide iodide [71-81-8]; Down 200; 8.4uM; HL60; HT_HG-U133A

SETD1A FLT4 HIVEP2 SEPTIN9 TIGD6 PRKCZ

2.11e-041979862720_DN
DrugPiribedil hydrochloride [78213-63-5]; Up 200; 12uM; MCF7; HT_HG-U133A

SETD1A FKBP15 SEPTIN9 PCLO ADAMTS20 ZNF304

2.11e-041979863512_UP
DrugScopolamin-N-oxide hydrobromide [6106-81-6]; Down 200; 10uM; MCF7; HT_HG-U133A

CACNA2D2 EMID1 LAMA3 N4BP3 EHBP1L1 DDX54

2.11e-041979862262_DN
DrugPentolinium bitartrate [52-62-0]; Down 200; 7.4uM; MCF7; HT_HG-U133A

HDAC5 SEPTIN9 N4BP3 TIGD6 CD22 DDX54

2.11e-041979864699_DN
DrugNimesulide [51803-78-2]; Down 200; 13uM; HL60; HG-U133A

ZNF410 DCAF8 MAP1A LPIN2 TMF1 FUT6

2.17e-041989861428_DN
DrugTalampicillin hydrochloride [39878-70-1]; Up 200; 7.8uM; MCF7; HT_HG-U133A

FBXO40 NCAPH2 TEP1 KLHL20 CD22 ZNF304

2.17e-041989863515_UP
DrugDelcorine; Up 200; 8.4uM; HL60; HT_HG-U133A

MAP1A NCAPH2 ATP10A ZFX CD22 CCDC40

2.17e-041989862178_UP
DrugLactobionic acid [96-82-2]; Down 200; 11.2uM; MCF7; HT_HG-U133A

PAPPA2 SETD1A SEPTIN9 NCAPH2 CD22 DDX54

2.17e-041989863246_DN
Drugalpha-Santonin [481-06-1]; Down 200; 16.2uM; MCF7; HT_HG-U133A

PAPPA2 HIVEP2 ALS2CL ZFX GYG2 ZNF304

2.17e-041989864353_DN
DrugMelatonin [73-31-4]; Down 200; 17.2uM; MCF7; HT_HG-U133A

HDAC5 SEPTIN9 WDR55 LAMA3 NCAPH2 GYG2

2.17e-041989865393_DN
DrugPinacidil [85371-64-8]; Up 200; 16.4uM; MCF7; HT_HG-U133A

EMID1 NCAPH2 ATP10A MAP3K12 ZFX LPIN2

2.17e-041989867437_UP
DrugRapamycin; Up 200; 0.1uM; HL60; HT_HG-U133A

PCLO EMID1 IGF2BP2 SCN5A FUT6 CCDC40

2.17e-041989866201_UP
DrugClofilium tosylate [92953-10-1]; Up 200; 7.8uM; PC3; HT_HG-U133A

NCAPH2 TEP1 KLHL20 ZFX KDR TNFSF15

2.17e-041989864492_UP
DrugLY 294002; Up 200; 0.1uM; MCF7; HT_HG-U133A

SETD1A WDR7 EMID1 TIGD6 IRF9 FUT6

2.17e-041989866935_UP
DrugSuramin sodium salt; Down 200; 10uM; PC3; HT_HG-U133A

SETD1A ANKFY1 MAP1A NCAPH2 CD22 CCDC40

2.17e-041989867501_DN
DrugMifepristone [84371-65-3]; Up 200; 9.4uM; MCF7; HT_HG-U133A

PAPPA2 MAP1A N4BP3 ZNF711 FBN1 FUT6

2.17e-041989863185_UP
DrugSulfamethoxazole [723-46-6]; Down 200; 15.8uM; PC3; HT_HG-U133A

GRWD1 MAP1A NCAPH2 TEP1 MAP3K12 DDX54

2.17e-041989867366_DN
DrugTolfenamic acid [13710-19-5]; Up 200; 15.2uM; PC3; HT_HG-U133A

PAPPA2 FBXO40 NCAPH2 FBN1 CD33 CCDC40

2.17e-041989866354_UP
DrugOndansetron Hydrochloride [103639-04-9]; Up 200; 12.2uM; MCF7; HT_HG-U133A

SETD1A FLT4 NCAPH2 KLF9 LPIN2 FUT6

2.17e-041989866270_UP
DrugMetixene hydrochloride [1553-34-0]; Down 200; 11.6uM; MCF7; HT_HG-U133A

PAPPA2 SETD1A CACNA2D2 NCAPH2 EHBP1L1 GYG2

2.17e-041989863313_DN
DrugMesoridazine besylate [32672-69-8]; Up 200; 7.4uM; MCF7; HT_HG-U133A

PCLO EMID1 WDR55 TEP1 KLHL20 FGA

2.17e-041989862874_UP
DiseaseHEMANGIOMA, CAPILLARY INFANTILE, SOMATIC

FLT4 KDR

1.05e-052962C4016109
Diseaselymphangioma (is_marker_for)

FLT4 KDR

1.05e-052962DOID:1475 (is_marker_for)
DiseaseHEMANGIOMA, CAPILLARY INFANTILE

FLT4 KDR

3.14e-053962602089
DiseaseHEMANGIOMA, CAPILLARY INFANTILE

FLT4 KDR

3.14e-053962C1865871
DiseaseCapillary infantile hemangioma

FLT4 KDR

3.14e-053962cv:C1865871
Diseasemean reticulocyte volume

SETD1A INTU NCAPH2 FAF1 TIGD6 FBXO38 IGF2BP2 LPIN2 ELF1 TRIM37

2.77e-047999610EFO_0010701
DiseaseVentricular Dysfunction

IGF2R DMD

2.90e-048962C0242973
DiseaseDental enamel hypoplasia

SEMA5B MAP3K21

6.77e-0412962EFO_1001304
Diseasethyroid gland carcinoma (is_marker_for)

FLT4 KDR

6.77e-0412962DOID:3963 (is_marker_for)
Disease5-methyluridine (ribothymidine) measurement

PCLO NCAPH2

9.29e-0414962EFO_0020013
Diseasecarcinoma (implicated_via_orthology)

FLT4 KDR PRKCZ

1.20e-0364963DOID:305 (implicated_via_orthology)
Diseasebody mass index, type 2 diabetes mellitus

FAF1 IGF2BP2

1.22e-0316962EFO_0004340, MONDO_0005148
DiseaseSclerocystic Ovaries

FLT4 DDX54 TMF1 DMD

1.28e-03144964C1136382
DiseasePolycystic Ovary Syndrome

FLT4 DDX54 TMF1 DMD

1.28e-03144964C0032460
Diseaseintraocular pressure measurement

SEPTIN9 PCLO EMID1 ADGRB2 FBN1 ADAMTS20 BOD1L1

1.39e-03509967EFO_0004695
DiseaseConventional (Clear Cell) Renal Cell Carcinoma

ZNF536 FLT4 ROR1 KDR

1.41e-03148964C0279702
Diseaseserum IgG glycosylation measurement

CACNA1E INTU HIVEP2 RALGAPA2 FUT6 ANKFN1 CCDC40

1.62e-03523967EFO_0005193
Diseaseunipolar depression, bipolar disorder

CACNA1E ZNF536 PCLO TENM4

1.71e-03156964EFO_0003761, MONDO_0004985
Diseasenicotine dependence symptom count, depressive symptom measurement

PCLO IGF2BP2 ANKFN1

1.90e-0375963EFO_0007006, EFO_0009262
Diseaseserum albumin measurement

FLT4 MAP1A PLEKHM1 IGF2BP2 EHBP1L1 SEMA5B PCNT

3.23e-03592967EFO_0004535

Protein segments in the cluster

PeptideGeneStartEntry
ETASVEMLPEHGSCR

TNFSF15

11

O95150
EDSIFTMADRGECVP

AMBP

176

P02760
QMGVCRADESEDSPD

ADGRB2

1216

O60241
SCERTHPEDSVGSME

ALS2CL

641

Q60I27
EERGDMSICLPATSV

BDP1

2326

A6H8Y1
PEGEAARTSTMQDET

ELF1

396

P32519
DMGRVISQSEPDLSC

CACNA1E

1041

Q15878
EAEGSPETRESSCVM

CACNA2D2

1001

Q9NY47
EEHSCVETGSQEPMT

ACSM4

211

P0C7M7
MVEYCTPTTSGEDVR

DMD

3356

P11532
VCSLEASGEPSTVDM

ATP10A

1361

O60312
DMVEDGTPCGTETHD

ADAMTS20

671

P59510
VCSDSLESPDEDMGS

KLF9

81

Q13886
VDAICTRGADMSVPD

ANKFY1

671

Q9P2R3
DVCMADPEGLSSESG

MAP1A

2576

P78559
RGTIEAAMPECDRDS

LAMA3

1361

Q16787
EDMSASDSDDCIIPG

RPGRIP1L

1076

Q68CZ1
CETGEPMEAESGDTS

GRWD1

11

Q9BQ67
ETSSCSGAAPTVEMD

CD33

321

P20138
ESEESRMSGECPSAV

KRT79

451

Q5XKE5
STMPDLRAEEDQGEC

KCNG4

241

Q8TDN1
SECTSDVEPDTREMV

DDX54

71

Q8TDD1
SELCPVDIDMDGSTD

ITGAE

516

P38570
MESLTDSPEDRSRGE

PCLO

1701

Q9Y6V0
CPGEDMETAQTLSAR

FAM74A3

76

Q4VXF1
SSPEEMSGAEEGRET

DCAF8

21

Q5TAQ9
PVSMDSECEESLAAS

FKBP15

1051

Q5T1M5
ITAEDCTMEVTPGAE

FIP1L1

211

Q6UN15
SEMACETPNAGTRED

DCAF5

886

Q96JK2
MDTEDRPEASGVDTE

EHBP1L1

381

Q8N3D4
ATPEGTSEACRMILE

IGF2BP2

246

Q9Y6M1
SFTSAMSRGCVTEEE

RALGAPA2

486

Q2PPJ7
PELDRTLSECAEMSS

PCNT

1216

O95613
CSDTEATEAMAPDIL

PPP1R2

86

P41236
MASVASCDSRPSSDE

INTU

1

Q9ULD6
ACSPGGSEDSEAMEE

FBXO38

751

Q6PIJ6
EAMEEGDAESSVCPR

FBXO38

761

Q6PIJ6
EGRRSEDMIACPETE

GYG2

371

O15488
TVPSMETGDLCADTA

PAPPA2

761

Q9BXP8
EECDGLMATTASGDI

BOD1L1

2041

Q8NFC6
CQDSEGDMIFPAESS

FBH1

86

Q8NFZ0
ETGMDVTSRCTLGDP

KLHL20

16

Q9Y2M5
CRTLVSAVPEESEMD

DOCK7

96

Q96N67
VSGEMDDNSLSPEAC

FBN1

2701

P35555
PSTEEGAMAERVESE

CCDC40

251

Q4G0X9
GRSDPSCASEHEMRV

C3orf80

171

F5H4A9
SEMVPGTADCNITAD

FUT6

81

P51993
SPREEMTTSSIICDI

DTHD1

131

Q6ZMT9
ERSDDMCSQGSEIPL

MAP3K12

786

Q12852
REATEEEPTMNGETS

FBXO40

151

Q9UH90
EVVTSEDGSDCPEAM

FGA

481

P02671
CRLVAEPSGSESSME

IRF9

241

Q00978
GVSCEEASSASLEPM

EMID1

101

Q96A84
PTSATDDSMCLAESG

FAF1

241

Q9UNN5
MSSDSDRQCPVDGDI

GADL1

1

Q6ZQY3
MPREGSTESESTQED

HDAC5

571

Q9UQL6
EERFNESGDPSCVIM

SART3

461

Q15020
SLSEECSLEPVTVAM

CABLES2

371

Q9BTV7
REGDSVTMTCEVSSS

CD22

256

P20273
TSSDAESREEVPMCS

FAM120B

331

Q96EK7
ESREEVPMCSDAESR

FAM120B

336

Q96EK7
MDATACNESVDGSPV

OR2AT4

1

A6NND4
PDEVRMDGCTLTDEQ

IGF2R

1796

P11717
EPMSCDSDLGTANAE

PLEKHM1

286

Q9Y4G2
PEEGMSSDSDIECDT

TRIM37

896

O94972
GIVPMEFAECDTESA

TIGD6

376

Q17RP2
PCMGDRFSEVAAVSE

SPAG5

176

Q96R06
MTAGSPEECGEVRRS

TMEM200B

1

Q69YZ2
LVDSAPVTCDSEMLT

MAP3K21

821

Q5TCX8
TPEDSCSEGSTADMT

SCN5A

1131

Q14524
EICSSGMDPNSDDSS

SGO1

116

Q5FBB7
ATEAAPSCVGDMADT

SEPTIN9

241

Q9UHD8
PCSSGDDMEISDDDR

SETD1A

576

O15047
GSESMESVDHTSDCP

ANKFN1

661

Q8N957
DTGRTEEQPMEVSVC

NCAPH2

216

Q6IBW4
MRSPHSDVGCSSDED

ROR1

566

Q01973
GERSEGEAMEICSEP

ZNF511

196

Q8NB15
SPETPEMSDEDSCVA

PRSS53

281

Q2L4Q9
AEMEESGRSATPVNC

TMF1

391

P82094
DCSGSRPLLMESEEE

nan

56

Q6ZSR9
PSTCRESDASMDSDA

TEP1

2521

Q99973
EDTPAVDGSTDTDRM

MINDY4

311

Q4G0A6
CRDTETTEAMAPDIL

PPP1R2B

86

Q6NXS1
EASECSRLMLPDDTT

ZNF410

46

Q86VK4
CQSTRPMLETDAEAG

SOGA1

371

O94964
EEEVCMAPRSSQSSE

FLT4

1181

P35916
DLTSARPLSCDSVMD

TENM4

1386

Q6N022
ESEAECATSGHEDMP

RXRG

221

P48443
VILPASSMEEATDCA

SEMA5B

1016

Q9P283
MEEASLCLGVSSAEP

ZNF536

1

O15090
MDRTCEERPAEDGSD

WDR55

1

Q9H6Y2
TMDTESEIDPCKVDG

ZFX

231

P17010
TSPVSCMEEEEVCDP

KDR

1196

P35968
SFTCREEGMDLPDSS

ZNF304

166

Q9HCX3
KESSRETTPEGRMAC

TMEM169

136

Q96HH4
QDCVSGVDSPTMVSE

ZNF711

146

Q9Y462
KSVGDEEDTPMICSS

HIVEP2

701

P31629
DDDITTGCLSSVPQM

WDR7

1096

Q9Y4E6
VDSEGDPCTVSSQME

PRKCZ

61

Q05513
TECLSDSAMDLPDVT

LPIN2

456

Q92539
SCSSAEEMGAVLPET

N4BP3

251

O15049
SSCSVMSEEPEGRSY

NECTIN4

431

Q96NY8